SCHEMBL4136458

SCHEMBL4136458

Cc1cccc(-c2ccc3c(c2)CCC(N2CCCC2)C3)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 1/20 0.45
HTR1A P08908 1/20 0.41
HTR7 P34969 1/20 0.41
LMNA P02545 1/20 0.41
KDM2B Q8NHM5 1/20 0.41
GRIN2B Q13224 2/20 0.41
HTR1D P28221 2/20 0.40
SIGMAR1 Q99720 1/20 0.40
DRD2 P14416 1/20 0.39
PARP10 Q53GL7 1/20 0.39
PARP11 Q9NR21 1/20 0.39
CYP1A2 P05177 2/20 0.38
CYP11B1 P15538 2/20 0.38
CYP11B2 P19099 2/20 0.38
CYP3A4 P08684 1/20 0.38
CYP2C9 P11712 1/20 0.38
CYP2B6 P20813 1/20 0.38
FAAH O00519 1/20 0.38
CYP2D6 P10635 1/20 0.37
CYP2C19 P33261 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4136016 0.89 HTR1D (0.41) HTR1AHTR7LMNAGRIN2BHTR1D
SCHEMBL4145248 0.86 GRIN2B (0.51) HRH3HTR1AHTR7GRIN2BHTR1D
SCHEMBL13102476 0.84 LMNA (0.47) HTR1AHTR7LMNAGRIN2BHTR1D
SCHEMBL4141125 0.84 HTR1A (0.47) HRH3HTR1AHTR7KDM2BGRIN2B
SCHEMBL4139998 0.84 HRH3 (0.45) HRH3HTR1AHTR7KDM2BGRIN2B
SCHEMBL4142789 0.84 HTR7 (0.41) HTR1AHTR7LMNAGRIN2BHTR1D
SCHEMBL4137087 0.84 HTR1D (0.41) HTR1AHTR7LMNAGRIN2BHTR1D
SCHEMBL4128005 0.84 CD274 (0.50) HRH3HTR1AKDM2BSIGMAR1
SCHEMBL4135883 0.84 HTR1D (0.40) HTR1AHTR7LMNAGRIN2BHTR1D
SCHEMBL4141100 0.83 HRH3 (0.38) HRH3LMNAKDM2BSIGMAR1DRD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090163482-A1 TETRALINES ANTAGONISTS OF THE H-3 RECEPTOR MCHARDY STANTON FURST 2009-06-25 US claimed
EP-2007749-A2 TETRALINES ANTAGONISTS OF THE H-3 RECEPTOR Pfizer Products Inc. (US) 2008-12-31 EP claimed
WO-2007105053-A2 TETRALINES ANTAGONISTS OF THE H-3 RECEPTOR PFIZER PRODUCTS INC. (US) 2007-09-20 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090163482-A1 TETRALINES ANTAGONISTS OF THE H-3 RECEPTOR HRH3, HRH4, HRH1 HRH3 1/4885HTR1A 19/4885HTR7 7/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.